Raptiva marketing authorisation suspended

The European Medicines Agency (EMEA) has recommended that the marketing authorisation for Raptiva be suspended across Europe following a review by its Committee for Medicinal Products for Human Use (CHMP) which concluded that the benefits of Raptiva no longer outweigh its risks.

The CHMP reviewed Raptiva after receiving reports of serious side effects including three confirmed cases of progressive multifocal leukoencephalopathy (PML) in patients who had been receiving Raptiva for more than three years, two of which were fatal. The CHMP reviewed information that had become available through post-marketing experience and ongoing clinical trials. As it was not possible to determine which patients are more susceptible to developing PML it was decided that introducing restrictions on those able to receive the drug would not be appropriate.

Prescribers should not issue any prescriptions for Raptiva to patients not already receiving it and should review the treatment of all patients currently taking the medicine with a view to stopping it. However, treatment should not be stopped abruptly as this could result in the psoriasis returning or worsening. Alternative treatments should be considered and the patient's condition should be monitored. Patients should be closely monitored for infections and neurological symptoms after they have ceased treatment as the effects of efalizumab can last for about eight to 12 weeks.

Further information: EMEA Q&A on Raptiva suspension

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases